Gulnihan Kupik1, Osman Kupik2, Kadri Altundag3
1Department of Radiation Oncology, Sitki Kocman University Hospital, Mugla, Turkey.
2Department of Nuclear Medicine, Sitki Kocman University Hospital, Mugla, Turkey.
3MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey.
Summary
Purpose: This study aimed to evaluate male breast cancer patients concerning clinicopathological and treatment parameters and determine progression-free survival (PFS) and the parameters influencing it.
Methods: A retrospective analysis was conducted on the treatment files of 32 male breast cancer patients diagnosed histopathologically between June 2006 and June 2021. Clinicopathologic features and treatment characteristics were evaluated. The primary endpoint was to determine PFS and the statistically significant influencing parameters. PFS analysis was performed using the Kaplan-Meier method, and the effects of parameters were compared using log-rank analysis.
Results: The median age of the patients was 56 years (range: 33-88). The median tumor size was 2.6 cm (range: 0.6-7). Hormone receptor (HR) positive and HER2 negative tumors were observed in 25 patients (78.1%), HER2 positive in 6 patients (18.8%), and only one patient (3.1%) had triple-negative breast cancer. The median follow-up time was 26 months (range: 3-121). Median PFS was 22 months, and the 2-year PFS rate was 72%. A statistically significant correlation was found between PFS and tumor size (p=0.042). The 2-year PFS was 100% in patients with tumor size less than 3 cm and 55% in patients with tumor size 3 cm and above.
Conclusion: In this study, male breast cancer patients were younger compared to Western series. Clinicopathological and treatment features were consistent with the literature. Tumor size (≥3cm) was identified as a prognostic factor affecting PFS.
Keywords: male breast cancer, diagnosis, treatment, progression-free survival.
Free Text: PDF